Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish Orphan Biovitrum and LFB Biomedicaments (LFB) have launched a new product Willfact for treatment of the bleeding disorder von Willebrand disease in Germany. The companies have also reported the prolongation of the current distribution agreement through 2014.
Subscribe to our email newsletter
Swedish Orphan Biovitrum is expected to distribute Willfact in Germany, Sweden, Norway, Iceland, Denmark, Estonia, Latvia, Lithuania, Czech Republic, Slovakia, Hungary and Bulgaria, under the agreement with LFB.
A Mutual Recognition Procedure is planned in the forthcoming months to secure marketing authorisation in the majority of the other countries where Swedish Orphan Biovitrum has the right to distribute Willfact.
Martin Nicklasson, CEO of Swedish Orphan Biovitrum Group, said: “The opportunity of making Willfact available to patients with von Willebrand disease in Germany and elsewhere will be a valuable contribution to improving the life of these patients. We look forward to a fruitful and continued partnership with LFB, as other products of value for rare diseases are also involved in this partnership and we see Willfact as an important addition to our emerging Hemophilia franchise.”
Pierre-Francois Falcou, senior international director of LFB Group, said: “The know-how of Swedish Orphan Biovitrum in hospital care and therapeutic proteins marketing is a key asset in increasing the availability of our Willfact product to the patient community in the selected countries. LFB as a key European player in bleeding disorders will benefit from this partnership.”